BioCentury | Jun 18, 2020
Emerging Company Profile
Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer
...also demonstrated that reducing IL-11 levels in mice could reduce cardiac and renal fibrosis (see “IL-11...
...and DC Investment Partners CEO: Mark Barrett Patents: Undisclosed Targets IL-11 - Interleukin-11 IL-11R - Interleukin-11 receptor...
...IL-11R - Interleukin-11 receptor PD-1 (PDCD1; CD279) - Programmed cell death 1 Sandi Wong, Assistant Editor Frazier Healthcare Partners Interleukin-11 (IL-11) receptor Lassen...
...and DC Investment Partners CEO: Mark Barrett Patents: Undisclosed Targets IL-11 - Interleukin-11 IL-11R - Interleukin-11 receptor...
...IL-11R - Interleukin-11 receptor PD-1 (PDCD1; CD279) - Programmed cell death 1 Sandi Wong, Assistant Editor Frazier Healthcare Partners Interleukin-11 (IL-11) receptor Lassen...